Israeli pharmaceutical company Kamada has announced positive results of its Phase I/II clinical trial of the company’s AAT protein, the active ingredient in its drug Glassia. The results indicate that the drug may halt the progression of the disease and enable the pancreas to continue excreting insulin.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments